00000nam 2200000zi 4500 9.933796 CaOODSP 20240725133201 m o d f cr |n||||||||| 240212e202403 onca ob f000 0 eng d 9780660702100 CaOODSP eng rda CaOODSP n-cn--- H164-327/2024E-PDF Guidance on nitrosamine impurities in medications. Ottawa, ON : Health Canada = Santé Canada, March 2024. ©2024 1 online resource (iii, 56 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. Issued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments. "Date Adopted: 2024-03-15. Effective Date: 2024-03-15." "Pub.: 230750." Includes bibliographical references. "Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover. Nitrosoamines Risk assessment Canada. Drugs Risk assessment Canada. Biologicals Risk assessment Canada. Radiopharmaceuticals Risk assessment Canada. Pharmaceutical policy Canada. Canada. Health Canada, issuing body. Lignes directrices sur les impuretés de nitrosamine dans les médicaments. (CaOODSP)9.933797 Guidance on nitrosamine impurities in medications. (May 2024) (CaOODSP)9.938524 Guidance on nitrosamine impurities in medications. (October 2023) (CaOODSP)9.928221 PDF 1.13 MB https://publications.gc.ca/collections/collection_2024/sc-hc/H164-327-2024-eng.pdf